Literature DB >> 33179005

Voluminous abdominal gastrointestinal stromal tumor of unknown origin manifested with bleeding in a young man: synchronous management of the emergency and oncological approach-case report.

Silvia Ferro1, Nicolò Fabbri2, Roberto Galeotti3, Elisabetta Salviato3, Giorgio Cavallesco1, Giancarlo Pansini1.   

Abstract

Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal tract, which cover about 1-2% of gastrointestinal neoplasms with an unadjusted incidence of around 1/100,000/year. They are also the most common non-epithelial neoplasms of the gastrointestinal tract and they are associated with a high rate of malignant transformation. They are more common in the stomach (40-60%) while a minor part repeatedly involves jejunum/ileus (25-30%), duodenum (5%), colorectal (5-15%) and esophagus (<1%). There are also much rarer extragastrointestinal stromal tumor (EGIST): these tumors have immunohistochemical and molecular characteristics similar to GISTs and for this reason, they are called this way, EGIST can involve retroperitoneum, mesentery, and omentum, without affecting the gastrointestinal tract. The clinical presentation depends on the primary localization of the neoplasm, however in 18% it is asymptomatic, and it is accidentally discovered during endoscopies, radiological examinations or surgical operations performed for other reasons, especially if it is small in size. More often, they are associated with non-specific symptoms such as early satiety, nausea or vomiting. Gastrointestinal bleeding is the most dangerous complication, often necessitating emergency surgery. The purpose of this case report is to describe our experience in the management of a young patient with gastrointestinal bleeding caused by an unknown voluminous retroperitoneal GIST with metastatic progression using a combined endovascular embolization and debulking-surgery approach for emergency and imatinib therapy combined with radiofrequency for the oncological approach. GIST requires multidisciplinary management, which improves both prognosis and quality of life. 2020 AME Case Reports. All rights reserved.

Entities:  

Keywords:  Gastrointestinal stromal tumor (GIST); case report; embolization; emergency surgery; radiofrequency procedure

Year:  2020        PMID: 33179005      PMCID: PMC7608730          DOI: 10.21037/acr-20-70

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  16 in total

Review 1.  A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

Authors:  Eytan Ben Ami; George D Demetri
Journal:  Expert Opin Drug Saf       Date:  2016-02-27       Impact factor: 4.250

2.  Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.

Authors:  Peter Reichardt; Marcus Schlemmer; Juan R Delgado Perez; Zsuzsanna Papai; Jana Prausova; Bohuslav Melichar; Elena Fumagalli; Carlo Barone; Sebastian Bauer; Anette Pustowka; Stefania Crippa; Ramon Castellana; Claudia Quiering; Axel Le Cesne
Journal:  Oncol Res Treat       Date:  2019-09-24       Impact factor: 2.825

Review 3.  Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response.

Authors:  Federica Vernuccio; Adele Taibbi; Dario Picone; Ludovico LA Grutta; Massimo Midiri; Roberto Lagalla; Giuseppe Lo Re; Tommaso Vincenzo Bartolotta
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

4.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; N Abecassis; H T Aro; S Bauer; R Biagini; S Bielack; S Bonvalot; I Boukovinas; J V M G Bovee; T Brodowicz; J M Broto; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; M Eriksson; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; B Kasper; K Kopeckova; D A Krákorová; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

5.  Management of liver metastases of gastrointestinal stromal tumors (GIST).

Authors:  Nikolaos Vassos; Abbas Agaimy; Werner Hohenberger; Roland S Croner
Journal:  Ann Hepatol       Date:  2015 Jul-Aug       Impact factor: 2.400

Review 6.  A systematic review on the clinical diagnosis of gastrointestinal stromal tumors.

Authors:  Marco Scarpa; Matteo Bertin; Cesare Ruffolo; Lino Polese; Davide F D'Amico; Imerio Angriman
Journal:  J Surg Oncol       Date:  2008-10-01       Impact factor: 3.454

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version.

Authors:  Toshirou Nishida; Seiichi Hirota; Akio Yanagisawa; Yoshinori Sugino; Manabu Minami; Yoshitaka Yamamura; Yoshihide Otani; Yasuhiro Shimada; Fumiaki Takahashi; Tetsuro Kubota
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402

9.  Extragastrointestinal stromal tumour (EGIST) presented as a mesenteric and retroperitoneal mass.

Authors:  Carlos Costa Almeida; Teresa Vieira Caroço; Miguel Albano; Luís Carvalho
Journal:  BMJ Case Rep       Date:  2019-12-02

Review 10.  Management of hemorrhage in gastrointestinal stromal tumors: a review.

Authors:  Qi Liu; Fanmin Kong; Jianping Zhou; Ming Dong; Qi Dong
Journal:  Cancer Manag Res       Date:  2018-04-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.